<scp>TAPO</scp> in first‐line osimertinib therapy and continuation of osimertinib-Reference-Cited by-同舟云学术

TAPO in first‐line osimertinib therapy and continuation of osimertinib

Published:2022-12-28 Issue:6 Volume:14 Page:584-591
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Mimura Chihiro¹^ORCID,Kaneshiro Kazumi²,Fujimoto Shodai¹³,Dokuni Ryota⁴,Iwamoto Natsuhiko⁵,Matsumura Kanoko⁵,Hatakeyama Yukihisa³,Kono Yuko²,Tachihara Motoko¹^ORCID

Affiliation:

1. Division of Respiratory Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan

2. Department of Respiratory Medicine Kita‐Harima Medical Center Ono‐City Japan

3. Department of Respiratory Medicine Akashi Medical Center Akashi Japan

4. Department of Respiratory Medicine Hyogo Prefectural Awaji Medical Center Sumoto Japan

5. Department of Respiratory Medicine Takatsuki General Hospital Osaka Japan

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14782

Reference25 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

3. Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations

4. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer

5. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease;JTO Clinical and Research Reports;2024-04

2. Safety of Readministration of EGFR-TKI After Onset of Interstitial Lung Disease in Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis;Clinical Lung Cancer;2024-01

3. Osimertinib;Reactions Weekly;2023-04-15